Cecilia Jones Joins LogicBio Therapeutics as Chief Economical Officer

LEXINGTON, Mass., Dec. 22, 2020 /PRNewswire/ — LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a medical stage genetic medicines company, these days declared the appointment of Cecilia Jones as the Company’s main money officer, powerful January 11, 2021.  Matthias Jaffe, the current CFO at LogicBio, will move down at the close of the yr and will stay a expert to the Enterprise throughout 2021.

“We are quite delighted that Cecilia Jones, a chief with comprehensive working experience in strategic finance and enterprise improvement in the daily life sciences sector, will be joining LogicBio as we enter an vital period of expansion options for the Corporation,” reported Fred Chereau, LogicBio president and CEO.  “We recently declared initiation of our section 1/2 Dawn medical demo for LB-001 in the treatment method of methylmalonic acidemia and concluded a successful adhere to-on public providing. As we expect extra critical milestones in 2021, Cecilia will participate in a central role in supporting these significant initiatives and supporting LogicBio system for a broad assortment of new advancement options.”

“I am thrilled to be joining LogicBio at this thrilling stage of the group as they do the job to lengthen the access of genetic medication,” reported Ms. Jones.  “I glimpse ahead to becoming a member of the leadership workforce and implementing my knowledge in world wide finance to assist the Business optimize these possibilities in the several years in advance.”

Ms. Jones has extra than 20 years of experience in consulting and monetary leadership roles with primary pharmaceutical and biotechnology organizations. She is currently vice president for R&D, around the globe professional medical and company improvement finance, at Biogen, advising senior management on investment prioritization to assist the Company’s strategic aims.  At Biogen she previously served as senior director company finance, exactly where she led world lengthy-array organizing and money assessment of enterprise development and M&A opportunities, and director of emerging markets finance, the place she supported Latin America, Asia Pacific and Japanese European markets. Prior to joining Biogen, Ms. Jones was director global finance at Genzyme (now Sanofi Genzyme), where she held a variety of functions of escalating duty in global finance. She received a Licenciatura en Economia from Universidad de San Andres in Buenos Aires, Argentina, and an MBA from Harvard Organization School.&#13

“On behalf of the board and administration workforce, I would like to lengthen our appreciation to Matthias Jaffe for his services as CFO at LogicBio all through our formative several years and for his commitment to doing the job with our team as a advisor through 2021 to assistance a sleek transition,” Mr. Chereau additional. 

About LogicBio Therapeutics 

LogicBio Therapeutics is dedicated to extending the achieve of genetic medication with groundbreaking platforms. LogicBio’s proprietary genome editing technological innovation platform, GeneRide, allows the web site-unique integration of a therapeutic transgene with no nucleases or exogenous promoters by harnessing the indigenous approach of homologous recombination. LogicBio has been given Fda clearance for the 1st-in-human medical demo of LB-001, a wholly owned genome modifying plan leveraging GeneRide for the cure of methylmalonic acidemia. Affected individual enrollment in the stage 1/2 Sunrise scientific demo is expected to commence in early 2021. In addition, LogicBio has a collaboration with Takeda to analysis and build LB-301, an investigational therapy leveraging GeneRide for the treatment of the scarce pediatric sickness Crigler-Najjar syndrome.

LogicBio is also acquiring a Following Generation Capsid platform for use in gene editing and gene therapies. Data presented have shown that the capsids deliver remarkably effective useful transduction of human hepatocytes with enhanced manufacturability with low amounts of pre-present neutralizing antibodies in human samples. Leading-tier capsid candidates from this energy have demonstrated major advancements above benchmark AAVs now in scientific advancement. LogicBio is building these highly potent vectors for inner improvement candidates and possibly for company enhancement collaborations.

Forward Wanting Statements  &#13

This push launch includes “ahead-looking” statements in the this means of the federal securities legal guidelines, which includes with respect to the Company’s administration transition, approaching improvement milestones and the timing of client enrollment in the period 1/2 Sunrise medical trial. These are not statements of historic details and are dependent on management’s beliefs and assumptions and on facts at the moment available. They are subject to risks and uncertainties that could lead to the actual benefits and the implementation of the Company’s ideas to range materially, which include the pitfalls linked with the initiation, charge, timing, progress and success of the Company’s present and future investigate and growth functions and preclinical research and possible foreseeable future clinical trials. These pitfalls are talked about in the Company’s filings with the U.S. Securities and Trade Commission (SEC), including, with out limitation, the Company’s Yearly Report on Variety 10-K submitted on March 16, 2020, the Company’s Quarterly Report on Form 10-Q submitted on May possibly 11, 2020, and the Firm’s subsequent filings with the SEC. Except as required by regulation, the Enterprise assumes no obligation to update these forward-searching statements publicly, even if new info gets to be obtainable in the upcoming. 

View original written content to obtain multimedia:https://www.prnewswire.com/information-releases/cecilia-jones-joins-logicbio-therapeutics-as-main-economical-officer-301197292.html&#13

Resource LogicBio Therapeutics, Inc.